Tag: herceptin market size

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Herceptin Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The herceptin market size has experienced robust growth in recent years. Its valuation is anticipated to rise from $7.1 billion in 2024 to $7.48 billion in 2025, achieving a compound annual growth rate (CAGR) of 5.4%. The expansion observed in the historic period is attributable to regulatory approvals, rising breast cancer incidence, advancements in monoclonal antibody technology, strong clinical trial outcomes, and increasing healthcare expenditure.

The herceptin market is projected for robust expansion over the coming years, anticipated to reach $9.38 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.8%. This growth during the forecast period is fueled by factors such as the broadening of biosimilar availability, greater uptake of targeted therapies, enhanced healthcare accessibility in developing economies, continuous research and development in oncology, and the increasing incidence of HER2-positive cancers. Key trends anticipated over the same period encompass the creation of antibody-drug conjugates, enhancements in biosimilar formulations, the incorporation of AI into drug discovery processes, personalized medicine strategies, and advancements in drug delivery mechanisms.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24236&type=smp

Which Factors And Drivers Are Influencing The Herceptin Market In 2025?

The rising occurrence of breast cancer is anticipated to propel the expansion of the herceptin market going forward. Breast cancer is a type of malignancy that develops in the cells of the breast, generally starting in the milk ducts or lobules, and encompasses forms such as invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and HER2-positive breast cancer. The increase in breast cancer cases is partly due to changes in lifestyle, including higher alcohol consumption, poor diet, and insufficient physical activity, all of which contribute to an elevated risk. As more individuals are diagnosed with breast cancer, particularly HER2-positive cases, the demand for effective targeted therapies like herceptin continues to escalate. For instance, in January 2025, according to the American Cancer Society, a US-based cancer organization, an estimated 319,750 new cases of breast cancer are expected to be reported in 2025, with approximately 42,680 deaths projected from the disease. Thus, the increasing incidence of breast cancer is driving the growth of the herceptin market.

What Are The Major Segment Types Covered In The Herceptin Market?

The herceptinmarket covered in this report is segmented –

1) By Product: Biologic; Biosimilar

2) By Application: Breast Cancer; Gastric Cancer

3) By Payer: Commercial And Private; Public

4) By Distribution Channel: Hospital Pharmacy; Specialty Pharmacy

Subsegments:

1) By Biologic: Intravenous (IV) Biologics; Subcutaneous (SC) Biologic

2) By Biosimilar: Intravenous (IV) Biosimilars; Subcutaneous (SC) Biosimilars

Which Competitive Trends Are Defining The Herceptin Market Structure?

Major companies operating in the herceptin market are actively pursuing novel therapeutic approaches, such as advanced biosimilar products, to broaden patient access and elevate treatment efficacy for HER2-positive cancers. Innovative biosimilar products are remarkably similar renditions of already approved biologic medications, manufactured through sophisticated biotechnology to guarantee equivalent safety, effectiveness, and quality. For instance, in April 2024, Accord BioPharma Inc., a US-based pharmaceutical company, secured approval from the U.S. Food and Drug Administration for HERCESSI (trastuzumab-strf), a biosimilar to herceptin (trastuzumab), intended for the management of HER2-overexpressing breast and gastric cancers. Biosimilars like HERCESSI demonstrate comparable effectiveness and safety when stacked against their reference biologics, simultaneously presenting the potential for more economical treatment alternatives.

Which Leading Companies Dominate The Herceptin Market Share?

Major companies operating in the herceptin market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim GmbH, Genentech Inc., Dr. Reddy’s Laboratories, Celltrion Healthcare, Mundipharma, Biocon Limited, Bio-Techne Corporation, Samsung Bioepis Co Ltd, AryoGen Pharmed, InvivoGen, Abnova Corporation, Shanghai Henlius Biotech Inc., Prestige Biopharma Pte Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/herceptin-global-market-report

How Do Regional Market Performances Compare Within The Herceptin Industry?

North America was the largest region in the herceptin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the herceptin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Herceptin Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24236&type=smp

Browse Through More Reports Similar to the Global Herceptin Market 2025, By The Business Research Company

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Skin Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Pancreatic Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Projected CAGR for the Herceptin Market Size from 2025 to 2034?

The size of the Herceptin market has significantly expanded over the last few years. The market, which is projected to rise from $7.1 billion in 2024 to $7.48 billion in 2025, is set to record a compound annual growth rate (CAGR) of 5.4%. This marked progression during the historical period can be accredited to regulatory authorizations, escalating cases of breast cancer, breakthroughs in monoclonal antibody technology, impressive results from clinical trials, and a surge in healthcare spending.

Anticipations are high for substantial surge in the herceptin market in the upcoming years. The prediction is that it will escalate to$9.38 billion by 2029 with a compound annual growth rate (CAGR) of 5.8%. The projected growth within the stated period can be traced to the extensive development of biosimilars, the surging adoption of goal-directed therapies, improved healthcare accessibility in developing markets, continuous oncology research and development, and the increasing cases of HER2-positive cancers. Key upcoming trends include the formulation of antibody-drug conjugates, progress in biosimilar formulas, the incorporation of artificial intelligence in drug discovery, personalized therapeutic strategies, and enhancement in drug delivery mechanisms.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24236&type=smp

What Are the Core Market Drivers Propelling Growth in the Herceptin Industry?

The herceptin market is poised for potential growth as breast cancer incidences continue to rise. Breast cancer, which usually originates in the milk ducts or lobules of the breast, includes invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and HER2-positive breast cancer. The uptick in breast cancer rates is somewhat attributed to lifestyle changes like higher alcohol intake, unhealthy dietary habits, and insufficient physical activity which escalate the risk. As more cases, particularly those that are HER2-positive, are diagnosed, the need for targeted therapies such as herceptin increases. For example, the American Cancer Society, a US-based cancer organization, predicted in January 2025 that approximately 319,750 new cases of breast cancer would be reported in 2025, with an estimated 42,680 deaths arising from the disease. Consequently, the climbing rates of breast cancer directly influence the growth of the herceptin market.

How Is the Herceptin Market Segmented?

The herceptinmarket covered in this report is segmented –

1) By Product: Biologic; Biosimilar

2) By Application: Breast Cancer; Gastric Cancer

3) By Payer: Commercial And Private; Public

4) By Distribution Channel: Hospital Pharmacy; Specialty Pharmacy

Subsegments:

1) By Biologic: Intravenous (IV) Biologics; Subcutaneous (SC) Biologic

2) By Biosimilar: Intravenous (IV) Biosimilars; Subcutaneous (SC) Biosimilars

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=24236&type=smp

Which Regions Are Driving the Next Phase of the Herceptin Market Growth?

North America was the largest region in the herceptin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the herceptin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Herceptin Industry?

Leading players in the herceptin market are working on creating cutting-edge treatment options, including ground-breaking biosimilar products, to increase patient accessibility and enhance therapeutic results for HER2-positive cancers. These inventive biosimilar items are very similar models of endorsed biologic drugs, created utilizing high-level biotechnology to ensure parallel safety, efficacy, and quality. For instance, in April 2024, Accord BioPharma Inc., a pharmaceutical company based in the US, gained approval from the U.S. Food and Drug Administration for HERCESSI (trastuzumab-strf), a herceptin (trastuzumab) biosimilar, for treating HER2-overexpressing breast and gastric cancers. Biosimilars like HERCESSI provide comparable safety and effectiveness to their reference biologics while potentially providing more economical treatment alternatives.

View the full report here:

https://www.thebusinessresearchcompany.com/report/herceptin-global-market-report

How Is the Herceptin Market Defined and What Are Its Core Parameters?

Herceptin, also known as trastuzumab, is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2/neu receptor, which promotes the growth of cancer cells. By binding to this receptor, herceptin inhibits tumor cell proliferation and flags them for destruction by the immune system.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24236

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Herceptin Market?

The market size for herceptin has notably expanded in the past few years. It is projected to increase from $7.10 billion in 2024 to $7.55 billion in 2025, representing a compound annual growth rate (CAGR) of 6.4%. The growth observed in the historic period is due to factors such as regulatory approvals, escalations in breast cancer incidences, advancements in monoclonal antibody technology, positive results from clinical trials, and the rise in healthcare spending.

What Growth Rate Is Forecasted for the Herceptin Market by 2029?

Expectations are high for robust growth in the Herceptin market over the next several years, with predictions reaching $9.59 billion in 2029 and demonstrating a compound annual growth rate of 6.1%. Several factors are contributing to this expected growth in the forecasted period, such as the proliferation of biosimilars, the increasing implementation of targeted therapies, enhanced access to healthcare in developing markets, progressive R&D in the field of oncology and an escalation in the rate of HER2-positive cancer cases. The predicted trends for this period include the production of antibody-drug conjugates, advancements in biosimilar compounds, incorporation of AI in the discovery of new drugs, approaches focusing on personalized medicine, and enhancements in drug delivery systems.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24236&type=smp

Which Key Companies Are Shaping the Future of the Herceptin Market?

Major companies operating in the herceptin market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim GmbH, Genentech Inc., Dr. Reddy’s Laboratories, Celltrion Healthcare, Mundipharma, Biocon Limited, Bio-Techne Corporation, Samsung Bioepis Co Ltd, AryoGen Pharmed, InvivoGen, Abnova Corporation, Shanghai Henlius Biotech Inc., Prestige Biopharma Pte Ltd.

Which Factors Are Driving Demand in the Herceptin Industry?

The surge in breast cancer cases is anticipated to stimulate the expansion of the herceptin market in the future. Breast cancer, a cancer that originates in the breast cells, typically in the milk ducts or lobules, encompasses invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and HER2-positive breast cancer. The escalation in breast cancer can be attributed in part to alterations in lifestyle, such as heightened alcohol intake, inadequate diet, and absence of physical activity, all of which contribute to an elevated risk. With the diagnosis of more individuals with breast cancer, especially HER2-positive instances, the need for powerful targeted treatments like herceptin is steadily increasing. For example, as per the American Cancer Society, a cancer organization based in the US, around 319,750 new breast cancer cases are forecasted for January 2025, and roughly 42,680 fatalities are predicted due to the disease. Consequently, the rising prevalence of breast cancer is facilitating the growth of the herceptin market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24236&type=smp

How Is the Herceptin Market Segmented by Several Divisions?

The herceptin market covered in this report is segmented –

1) By Product: Biologic, Biosimilar

2) By Application: Breast Cancer, Gastric Cancer

3) By Payer: Commercial And Private, Public

4) By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy

Subsegments:

1) By Biologic: Intravenous (IV) Biologics, Subcutaneous (SC) Biologic

2) By Biosimilar: Intravenous (IV) Biosimilars, Subcutaneous (SC) Biosimilars

What are the Emerging Market Trends Driving the Growth of the Herceptin Industry?

Key players in the herceptin market are advancing new treatment pathways, including groundbreaking biosimilar products, to boost patient accessibility and augment therapeutic results for HER2-positive cancers. Groundbreaking biosimilar products, which are almost identical substitutes of certified biologic drugs, are created using cutting-edge biotechnology to guarantee comparable safety, efficacy, and quality. For example, in April 2024, Accord BioPharma Inc., an American pharmaceutical company, gained approval from the U.S. Food and Drug Administration for HERCESSI (trastuzumab-strf), a herceptin (trastuzumab) biosimilar, for the treatment of HER2-overexpressing breast and gastric cancers. Biosimilars like HERCESSI exhibit similar efficacy and safety to their reference biologics while possibly providing more economical treatment alternatives.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/herceptin-global-market-report

Which Regions Are Driving Growth in the Herceptin Market?

North America was the largest region in the herceptin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the herceptin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/customise?id=24236&type=smp

This Report Delivers Insight On:

1. How big is the herceptin market, and how is it changing globally?

2. Who are the major companies in the herceptin market, and how are they performing?

3. What are the key opportunities and risks in the herceptin market right now?

4. Which products or customer segments are growing the most in the herceptin market?

5. What factors are helping or slowing down the growth of the herceptin market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

#What Is the Current and Projected Market Size of the Herceptin Market Through 2034?#_x000D_

In the past few years, the herceptin market has experienced significant expansion. The market is expected to increase from $7.10 billion in 2024 to $7.55 billion in 2025, boasting a compound annual growth rate (CAGR) of 6.4%. Various factors contributed to this growth during the historic period including regulatory approvals, a rise in breast cancer cases, progress in monoclonal antibody technology, positive results from clinical trials, and an uptick in healthcare spending._x000D_

_x000D_

The market size for herceptin is anticipated to experience significant growth in the forthcoming years. It is projected to expand to $9.59 billion by 2029, with a compound annual growth rate (CAGR) of 6.1%. Factors contributing to this growth in the prediction period include the proliferation of biosimilars, the escalating acceptance of target-based treatments, the growth of healthcare accessibility in emerging markets, continuing research and development in the oncology field, and the upward trend of HER2-positive cancer cases. The forecast period is also expected to see notable trends such as the progression of antibody-drug conjugates, advancements in biosimilar formulations, the incorporation of AI in drug discovery, the deployment of personalized medicine strategies and enhancements in drug delivery systems._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=24236&type=smp_x000D_

_x000D_

#What External and Internal Drivers Are Contributing to the Growth of the Herceptin Market?#_x000D_

The continued upward trajectory of breast cancer rates is poised to drive the growth of the herceptin market. Breast cancer takes root in the cells of the breast, typically originating in milk ducts or lobules, and encompasses invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and HER2-positive breast cancer. Lifestyle choices including enhanced alcohol intake, poor dietary habits, and insufficient physical activity are partially to blame for the surge in breast cancer, as they heighten the risk of developing the disease. With an increasing number of breast cancer diagnoses, especially those of the HER2-positive type, the call for potent targeted treatments like herceptin intensifies. For example, the American Cancer Society, a US-based cancer organization, estimates that in January 2025, around 319,750 new breast cancer cases will be recorded, leading to an approximation of 42,680 deaths resulting from the illness. Consequently, the growing occurrence of breast cancer facilitates the growth of the herceptin market._x000D_

_x000D_

#What Segment Types Define the Herceptin Market Structure?#_x000D_

The herceptin market covered in this report is segmented –_x000D_

_x000D_

1) By Product: Biologic, Biosimilar_x000D_

2) By Application: Breast Cancer, Gastric Cancer_x000D_

3) By Payer: Commercial And Private, Public_x000D_

4) By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy_x000D_

_x000D_

Subsegments:_x000D_

1) By Biologic: Intravenous (IV) Biologics, Subcutaneous (SC) Biologic_x000D_

2) By Biosimilar: Intravenous (IV) Biosimilars, Subcutaneous (SC) Biosimilars_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=24236&type=smp_x000D_

_x000D_

#Which Geographic Areas Hold the Strongest Growth Potential in the Herceptin Market?#_x000D_

North America was the largest region in the herceptin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the herceptin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Long-Term Trends Are Transforming the Competitive Landscape of the Herceptin Market?#_x000D_

Key companies in the herceptin market are striving to develop innovative solutions, such as cutting-edge biosimilar products, to increase patient accessibility as well as enhance therapeutic results for HER2-positive cancers. Innovative biosimilar products parallel approved biologic drugs closely and are manufactured using sophisticated biotechnology to guarantee similar safety, efficacy, and quality. For example, Accord BioPharma Inc., a pharmaceutical firm based in the US, gained approval for HERCESSI (trastuzumab-strf), a herceptin (trastuzumab) biosimilar, from the U.S. Food and Drug Administration in April 2024 for the treatment of breast and gastric cancers that overexpress HER2. Biosimilars like HERCESSI offer comparable safety and efficacy to their reference biologics while possibly presenting a more economical treatment choice._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/herceptin-global-market-report_x000D_

_x000D_

#What Is the Definition of the Herceptin Market?#_x000D_

Herceptin, also known as trastuzumab, is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2/neu receptor, which promotes the growth of cancer cells. By binding to this receptor, herceptin inhibits tumor cell proliferation and flags them for destruction by the immune system._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=24236&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model